Navigation Links
Ophthalmic Pharmaceutical Drugs - Global Strategic Business Report
Date:12/22/2013

DUBLIN, Dec. 22, 2013 /PRNewswire/ -- Research and Markets (http://www.researchandmarkets.com/research/wj54rz/ophthalmic#summary) has announced the addition of the "Ophthalmic Pharmaceutical Drugs - Global Strategic Business Report" report to their offering.

(Logo: http://photos.prnewswire.com/prnh/20130307/600769)

Ophthalmic pharmaceutical drugs is a uniquely competitive market kept perennially vibrant by refining technological changes in drug formulations and efficacy. Conventional drug delivery techniques are giving way to newer, and more effective therapies such as infusion-type medicines, slow-release delivery systems, and implantables.

The global market for ophthalmic drugs is witnessing substantial growth, due primarily to factors such as rising incidence as well as prevalence of eye disorders such as macular degeneration, diabetic retinopathy and presbyopia among the elderly population. Growth is also driven by the evolution of treatment options for age-macular degeneration, as well as the ensuing commercial and therapeutic success of Lucentis, which made the market more lucrative and a potential growth sector.

Conversely, the market is fraught with challenges, including absence of health insurance among the ageing population in developing countries. Meanwhile, low awareness related to ophthalmic disorders, primarily due to little or no awareness in rural areas, pose tremendous challenges for ophthalmic drugs market in developing countries.

The global ophthalmic drug market is likely to face a patent cliff after 2010 as patents of major products within ocular anti-allergic, anti-glaucoma, as well as anti-inflammatory/anti-inflective therapies expire. The market expansion and the development of ophthalmic franchises of major pharmaceutical providers would be hit by the ensuing generic incursion, along with the rising regulatory priorities with regards to the global healthcare reforms.

Though the high efficacy of Allegan/Inspire's Restasis and Roche/Genetech's Lucentis is likely to lead the markets for treatment of dry eye and wet Age-Macular Degeneration, respectively, the global ophthalmology treatment sales are expected to stay more or less flat during the ensuing years.


Key Topics Covered:

1. Introduction, Methodology & Product Definitions

2. Industry Overview

3. Market Dynamics

4. An Overview Of Ophthalmic Drugs

5. Ophthalmic Disorders: A Freeze Frame

6. Fda Approvals And Product Launches

7. Fda Approvals And Product Approvals Launches In The Recent Past - A Perspective Builder

8. Recent Industry Activity

9. Corporate Activity In Recent Past - A Perspective Builder

10. Focus On Select Global Players

11. Global Market Perspective

12. The United States

13. Canada

14. Japan

15. Europe

16. Asia-Pacific

17. Latin America

18. Rest Of World


Companies Mentioned:

  • Aurolab (India)
  • Bohus Biotech AB (Sweden)
  • Cynacon/OCuSOFT (USA)
  • E Fougera & co (USA)
  • Farmak PubJSC (Ukraine)
  • Farmigea SpA (Italy)
  • GSK Consumer Healthcare (Malaysia)
  • GenVec, Inc (USA)
  • Genaera Corporation (USA)
  • Gland Pharma Ltd (India)
  • Hemomont doo (Serbia and Montenegro)
  • Hi-Tech Pharmacal Co, Inc (USA)
  • ISTA Pharmaceuticals (USA)
  • Indkus Drugs And Pharma Pvt, Ltd (India)
  • Insite Vision, Inc (USA)
  • Inspire Pharmaceuticals, Inc (USA)
  • Laboratório Edol Produtos Farmacêuticos, SA (Portugal)
  • Miravant Medical Technology (USA)
  • NPS Pharmaceuticals (USA)
  • Nascent Pharmaceuticals, Inc (USA)
  • Novagali Pharma SA (France):
  • Novartis AG (Switzerland)
  • OSI Pharmaceuticals (USA)
  • Othera Pharmaceuticals (USA)
  • Otsuka Pharmaceutical (Japan)
  • Oxigene, Inc (USA)
  • Pfizer, Inc (USA)
  • QLT, Inc (Canada)
  • Rohto Pharmaceutical Company Ltd (Japan)
  • Sucampo Pharmaceuticals, Inc (USA)
  • Unimed Pharma Sro (Slovakia)
  • Ursapharm Arzneimittel GmbH & Co, KG (Germany)
  • Vitamed Pharmaceutical Industries Ltd (Israel)



For more information visit http://www.researchandmarkets.com/research/wj54rz/ophthalmic#summary



Media Contact:

Laura Wood , +353-1-481-1716, press@researchandmarkets.net




'/>"/>
SOURCE Research and Markets
Copyright©2012 PR Newswire.
All rights reserved

Related medicine technology :

1. Shire Reports Top-Line Results on OPUS-2, a Phase 3 Study Investigating the Use of Lifitegrast (5.0% Ophthalmic Solution) in Adults With Dry Eye Disease
2. Ophthalmic Instrumentation - Global Strategic Business Report - 2012 Featuring Abbott, Bausch & Lomb, Carl Zeiss and Others
3. VisionCare Ophthalmic Technologies Secures Up To $15MM To Accelerate Growth Of Its Novel Treatment For Age-Related Macular Degeneration
4. JHP Pharmaceuticals Enters Agreement to Produce Unique Late Stage Ophthalmic Product
5. Altaire Pharmaceuticals, Inc. Issues Voluntary Nationwide Recall of 9 lots of Carboxymethylcellulose Sodium 0.5% Ophthalmic Solution sold under several brands
6. Imprimis Pharmaceuticals, Inc. Acquires Intellectual Property for Ophthalmic Compound Development Opportunity
7. Ohr Pharmaceutical Announces Addition of Dr. John Wroblewski to Ophthalmic Scientific Advisory Board
8. Key Findings: Innovations in Ophthalmic Devices - Anterior Segment
9. Perrigo Company Acquires Ophthalmic Product Portfolio From Fera Pharmaceuticals, LLC For An Upfront Payment Of $93 Million
10. Sony Announces First East and West Coast Installations of 3D Imaging Solution for Ophthalmic Surgery
11. Brazil Ophthalmic Devices Market Outlook to 2018 - Vision Care, Intraocular Lens (IOL), Cataract Surgery Devices, Ophthalmic Diagnostic Equipment, Refractive Surgery Devices, Vitreo Retinal Surgery Devices and Others
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:3/28/2017)... 28, 2017 The U.S. Food and ... treat adults with moderate-to-severe eczema (atopic dermatitis). Dupixent ... controlled adequately by topical therapies, or those for ... be used with or without topical corticosteroids. ... to approving new and innovative therapies for patients ...
(Date:3/28/2017)... PHOENIX , March 28, 2017  Today, ... Pharmacy released a new white paper to ... use of latex in healthcare. Specifically, there is substantial confusion ... fact, the FDA has urged manufacturers to drop the term ... labels, because of the challenge to ensure a product is ...
(Date:3/28/2017)... March 28, 2017 The global ... landscape, with the top three companies, namely Shimadzu Corporation, ... a significant 49% of the overall market in 2015, ... vendor landscape is intensely competitive and has few players, ... market. These factors have restricted the entry of new ...
Breaking Medicine Technology:
(Date:3/28/2017)... (PRWEB) , ... March 28, 2017 , ... ... in Wethersfield, Conn., has relocated its corporate headquarters to a new, more expansive ... , In October 2016, Qualidigm purchased a distressed office building in Wethersfield, ...
(Date:3/28/2017)... Billerica, MA (PRWEB) , ... March 28, 2017 ... ... instrument for direct measurement of corrosive ions found in power plant water and ... plant components such as turbines and boilers, leading to extensive maintenance and unplanned ...
(Date:3/28/2017)... ... , ... Columbus OH. Dr. Justin Harper, Founder of Juvly Aesthetics in Ohio ... country to sit on the 2017 National Advisory Board for Allergan’s Facial Aesthetics National ... helped propel the clinic from a small start-up to number 78 in the country ...
(Date:3/28/2017)... ... 28, 2017 , ... Prominant bariatric surgeon and well-known weight-loss ... offer the recently FDA-approved Obalon Balloon System to his patients. The Obalon is ... already comprehensive list of weight-loss services. Dr. Liu is proud to announce ...
(Date:3/28/2017)... ... March 28, 2017 , ... With expansion and efficiency in ... early March. , The seed processing plant opened in Marshallville in 2006, and a ... new office allows opportunity for transition of Patten Seed operations to the Middle Georgia ...
Breaking Medicine News(10 mins):